The clinical development of vaccines for HER2 + breast cancer: Current landscape and future perspectives
Authors:
- 1 December 2017
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 61, 107-115
Abstract
No abstract availableKeywords
This publication has 81 references indexed in Scilit:
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast CancerNew England Journal of Medicine, 2012
- A Novel Dendritic Cell-based Immunization Approach for the Induction of Durable Th1-polarized Anti-HER-2/neu Responses in Women With Early Breast CancerJournal of Immunotherapy, 2012
- TLR2 Agonist PSK Activates Human NK Cells and Enhances the Antitumor Effect of HER2-Targeted Monoclonal Antibody TherapyClinical Cancer Research, 2011
- Clinical trial results of the HER‐2/neu (E75) vaccine to prevent breast cancer recurrence in high‐risk patientsCancer, 2011
- The significance of HER‐2/neu receptor positivity and immunophenotype in ductal carcinoma in situ with early invasive diseaseJournal of Surgical Oncology, 2011
- Asymptomatic changes in cardiac function can occur in ductal carcinoma-in-situ patients following treatment with HER-2/neu–pulsed dendritic cell vaccinesThe American Journal of Surgery, 2009
- HER-2/neu Overexpression as a Predictor for the Transition from In situ to Invasive Breast CancerCancer Epidemiology, Biomarkers & Prevention, 2009
- Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapyNature Medicine, 2007
- Expression of the HER1–4 family of receptor tyrosine kinases in breast cancerThe Journal of Pathology, 2003